Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Autor: Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, Roland Fenk, Eva Nievergall, Diana Tichy, Britta Besemer, Jan Dürig, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Anne M Asemissen, Bernhard Heilmeier, Niels Weinhold, Stefanie Huhn, Katharina Kriegsmann, Steffen P Luntz, Tobias A W Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Müller, Cyrus Khandanpour, Wolfgang Knauf, Christof Scheid, Markus Munder, Thomas Geer, Hendrik Riesenberg, Jörg Thomalla, Martin Hoffmann, Marc S Raab, Hans J Salwender, Katja C Weisel, Joachim Behringer, Helga Bernhard, Christiane Bernhardt, Igor W Blau, Claus Bolling, Daniel Debatin, Gerrit Dingeldein, Barbara Ferstl, Claudia Fest, Stefan Fronhoffs, Stephan Fuhrmann, Tobias Gaska, Martin Görner, Ullrich Graeven, Jochen Grassinger, Michael Heinsch, Gerhard Held, Olaf Hopfer, Peter Immenschuh, Dominic Kaddu-Mulindwa, Martine Klausmann, Stefan Klein, Yon-Dschun Ko, Georg Köchling, Michael Koenigsmann, Philippe Kostrewa, Doris Maria Kraemer, Stephan Kremers, Martin Kropff, Paul La Rosée, Rolf Mahlberg, Uwe Martens, Michael Neise, Holger Nückel, Wolfram Pönisch, Maria Procaccianti, Mohammed R Rafiyan, Peter Reimer, Armin Riecke, Mathias Rummel, Volker Runde, Markus Schaich, Christoph Scheid, Martin Schmidt-Hieber, Stefan Schmitt, Daniel Schöndube, Andreas Schwarzer, Peter Staib, Heike Steiniger, Dirk Sturmberg, Hans-Joachim Tischler, Arne Trummer, Barbara Tschechne, Walter Verbeek, Bettina Whitlock, Maike de Wit, Matthias Zaiß, Carsten Ziske

Publikováno v: The Lancet Haematology. 9:e810-e821

Anti-CD38 monoclonal antibodies have consistently shown increased efficacy when added to standard of care for patients with multiple myeloma. We aimed to assess the efficacy of isatuximab in addition to lenalidomide, bortezomib, and dexamethasone in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa4e06ca167ce956ab3c750cb5371c4d
https://doi.org/10.1016/s2352-3026(22)00263-0

Biomodulatory Treatment With Azacitidine, All-trans Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis

Autor: Sebastian Klobuch, Tim Steinberg, Emanuele Bruni, Carina Mirbeth, Bernhard Heilmeier, Lina Ghibelli, Wolfgang Herr, Albrecht Reichle, Simone Thomas

Publikováno v: Frontiers in Pharmacology, Vol 9 (2018)

Effective and tolerable salvage therapies for elderly patients with chemorefractory acute myeloid leukemia (AML) are limited and usually do not change the poor clinical outcome. We recently described in several chemorefractory elderly AML patients th

Externí odkaz: https://doaj.org/article/6c5083509dd9422c957961b7a722d8bb

Bone Marrow and Peripheral Blood Aberrant Plasma Cell Assessment by Next-Generation Flow Cytometry in MM Patients

Autor: Katharina, Kriegsmann, Calin, Manta, Ricarda, Schwab, Elias K, Mai, Marc S, Raab, Hans J, Salwender, Roland, Fenk, Britta, Besemer, Jan, Dürig, Roland, Schroers, Ivana, von Metzler, Mathias, Hänel, Christoph, Mann, Anne M, Asemissen, Bernhard, Heilmeier, Uta, Bertsch, Stefanie, Huhn, Carsten, Müller-Tidow, Hartmut, Goldschmidt, Michael, Hundemer

Publikováno v: Blood advances.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::994b1247a0b6418777ccce273942eb8b
https://pubmed.ncbi.nlm.nih.gov/35914229

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

Autor: Markus Munder, Roland Fenk, Mathias Haenel, Steffen Luntz, Wolfgang Knauf, Martin C. Mueller, Anne-Marie Asemissen, Eva Nievergall, Ivana von Metzler, Tobias A. W. Holderried, Uta Bertsch, Elias K. Mai, Niels Weinhold, Deniz Gezer, Christoph Mann, Katja Weisel, Martin Hoffmann, Hans Salwender, Hartmut Goldschmidt, Britta Besemer, Karolin Trautmann-Grill, Stefanie Huhn, Cyrus Khandanpour, Jan Dürig, Joerg Thomalla, Diana Tichy, Katharina Kriegsmann, Marc-Steffen Raab, Thomas Geer, Bernhard Heilmeier, Roland Schroers, Hendrik Riesenberg, Maika Klaiber-Hakimi

Publikováno v: Blood. 138:463-463

Background: In newly-diagnosed multiple myeloma (NDMM), lenalidomide/bortezomib/dexamethasone (RVd) is one of the most widely used combination regimens. Anti-CD38 monoclonal antibodies (CD38-moAb) increase efficacy when added to standard-of-care regi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::40acd634cbc8978c6878a405a39c237d
https://doi.org/10.1182/blood-2021-145097

The leukemogenicity of Hoxa9 depends on alternative splicing

Autor: Christiane Stadler, Vijay P.S. Rawat, Christian Buske, Lars Bullinger, Hartmut Döhner, K E Edmaier, Wolfgang Hiddemann, Michaela Feuring-Buske, K Döhner, Anna Dolnik, Naidu M. Vegi, Karsten Spiekermann, Leticia Quintanilla-Fend, Bernhard Heilmeier, Medhanie A. Mulaw

Publikováno v: Leukemia 28, 1838-1843 (2014)

Although the transforming potential of Hox genes is known for a long time, it is not precisely understood to which extent splicing is important for the leukemogenicity of this gene family. To test this for Hoxa9, we compared the leukemogenic potentia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3634d843afb4977382ba1701906ec765
https://doi.org/10.1038/leu.2014.74